Pacific Biosciences of California has seen its shares rise 11.6% since its last earnings report, outperforming the S&P 500, but the company cut its 2026 revenue guidance. In the second quarter of 2026, PacBio reported an adjusted loss per share of 14 cents, in line with estimates, while total revenues of $39 million missed the consensus by 4.2% and fell 2% year over year. The company lowered its full-year 2026 revenue outlook to $155-$165 million from a prior range of $165-$175 million, citing weaker instrument sales and a sharp revenue decline in Asia Pacific. Despite the revenue miss, consumables grew 6.3% to $20.1 million, and EMEA revenues jumped 52% to $14.4 million. Analysts have revised estimates downward by 8.33% over the past month, and the stock carries a Zacks Rank #4 (Sell).
Pacific Biosciences of CaliforniaCompany cut 2026 revenue guidance and missed Q2 revenue estimates.
Edwards Lifesciences Corp